David Carneros
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
David Carneros has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Matilde Bustos
Area of Liver, Digestive and Inflammatory Diseases, Institute of Biomedicine of Seville (IBIS), Spanish National Research Council (CSIC) - University of Seville (US) - Virgen del Rocio University Hospital (HUVR), Seville, Spain
3 shared publications - Maria Dolores Giraldez
Institute of Biomedicine of Seville (IBiS), Spanish National Research Council (CSIC), University of Seville, Virgen del Rocio University Hospital, Seville, Spain
2 shared publications - Christoph Garbers
Institute of Clinical Biochemistry, Hannover Medical School, Hannover, Germany
1 shared publication - Guillermo López-Lluch
Pablo de Olavide University
1 shared publication - Stefan Rose-John
Department of Biochemistry, Christian-Albrechts-Universität zu Kiel, Kiel, Germany
1 shared publication
Latest Publications
- Open Access
- 1 September 2021
- Published by Elsevier in Gastroenterology
- Vol. 161 (3) , 1063-1065
Gp130 Signaling in NOD2-Driven Crohn’s Disease: A Key Player in Fibrosis and a Novel Target for Refractory Patients
- 1 September 2021
- Published by Elsevier in Gastroenterology
- Vol. 161 (3) , 1063-1065
Open AccessGp130 Signaling in NOD2-Driven Crohn’s Disease: A Key Player in Fibrosis and a Novel Target for Refractory Patients
- 1 July 2021
- Published by Springer Nature in Nature Reviews Gastroenterology & Hepatology
- Vol. 18 (11) , 787-803
New insights into IL-6 family cytokines in metabolism, hepatology and gastroenterology
IL-6 family cytokines are defined by the common use of the signal-transducing receptor chain glycoprotein 130 (gp130). Increasing evidence indicates that these cytokines are essential in the regulation of metabolic homeostasis as well as in the pathophysiology of multiple gastrointestinal and liver disorders, thus making them attractive therapeutic targets. Over the past few years, therapies modulating gp130 signalling have grown exponentially in several clinical settings including obesity, cancer and inflammatory bowel disease. A newly engineered gp130 cytokine, IC7Fc, has shown promising preclinical results for the treatment of type 2 diabetes, obesity and liver steatosis. Moreover, drugs that modulate gp130 signalling have shown promise in refractory inflammatory bowel disease in clinical trials. A deeper understanding of the main roles of the IL-6 family of cytokines during homeostatic and pathological conditions, their signalling pathways, sources of production and target cells will be crucial to the development of improved treatments. Here, we review the current state of the role of these cytokines in hepatology and gastroenterology and discuss the progress achieved in translating therapeutics targeting gp130 signalling into clinical practice.
- 1 July 2021
- Published by Springer Nature in Nature Reviews Gastroenterology & Hepatology
- Vol. 18 (11) , 787-803
New insights into IL-6 family cytokines in metabolism, hepatology and gastroenterology
IL-6 family cytokines are defined by the common use of the signal-transducing receptor chain glycoprotein 130 (gp130). Increasing evidence indicates that these cytokines are essential in the regulation of metabolic homeostasis as well as in the pathophysiology of multiple gastrointestinal and liver disorders, thus making them attractive therapeutic targets. Over the past few years, therapies modulating gp130 signalling have grown exponentially in several clinical settings including obesity, cancer and inflammatory bowel disease. A newly engineered gp130 cytokine, IC7Fc, has shown promising preclinical results for the treatment of type 2 diabetes, obesity and liver steatosis. Moreover, drugs that modulate gp130 signalling have shown promise in refractory inflammatory bowel disease in clinical trials. A deeper understanding of the main roles of the IL-6 family of cytokines during homeostatic and pathological conditions, their signalling pathways, sources of production and target cells will be crucial to the development of improved treatments. Here, we review the current state of the role of these cytokines in hepatology and gastroenterology and discuss the progress achieved in translating therapeutics targeting gp130 signalling into clinical practice.
- Open Access
Physiopathology of Lifestyle Interventions in Non-Alcoholic Fatty Liver Disease (NAFLD)
Non-alcoholic fatty liver disease (NAFLD) is a major health problem, and its prevalence has increased in recent years. Diet and exercise interventions are the first-line treatment options, with weight loss via a hypocaloric diet being the most important therapeutic target in NAFLD. However, most NAFLD patients are not able to achieve such weight loss. Therefore, the requisite is the investigation of other effective therapeutic approaches. This review summarizes research on understanding complex pathophysiology underlying dietary approaches and exercise interventions with the potential to prevent and treat NAFLD.
Open AccessPhysiopathology of Lifestyle Interventions in Non-Alcoholic Fatty Liver Disease (NAFLD)
Non-alcoholic fatty liver disease (NAFLD) is a major health problem, and its prevalence has increased in recent years. Diet and exercise interventions are the first-line treatment options, with weight loss via a hypocaloric diet being the most important therapeutic target in NAFLD. However, most NAFLD patients are not able to achieve such weight loss. Therefore, the requisite is the investigation of other effective therapeutic approaches. This review summarizes research on understanding complex pathophysiology underlying dietary approaches and exercise interventions with the potential to prevent and treat NAFLD.